These insights underscore SIRT1’s potential as a therapeutic target, as its inhibition could not only reverse drug resistance but also disrupt essential oncogenic signaling pathways, thereby presenting promising avenues for the treatment of advanced PCa. This evidence concerns the gene SIRT1 and posterior cortical atrophy.